Your browser is no longer supported. Please, upgrade your browser.
Settings
VKTX Viking Therapeutics, Inc. daily Stock Chart
VKTX [NASD]
Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.65 Insider Own3.00% Shs Outstand54.40M Perf Week0.00%
Market Cap544.00M Forward P/E- EPS next Y-0.50 Insider Trans4.74% Shs Float48.80M Perf Month-19.74%
Income-18.90M PEG- EPS next Q-0.11 Inst Own36.10% Short Float19.87% Perf Quarter110.08%
Sales- P/S- EPS this Y12.50% Inst Trans0.99% Short Ratio2.67 Perf Half Y128.31%
Book/sh1.60 P/B6.25 EPS next Y-13.60% ROA-59.40% Target Price14.40 Perf Year800.90%
Cash/sh1.42 P/C7.02 EPS next 5Y40.00% ROE-79.70% 52W Range0.88 - 13.43 Perf YTD146.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-22.82% Beta-
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low1077.84% ATR0.92
Employees4 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)56.05 Volatility8.25% 8.52%
OptionableYes Debt/Eq0.05 EPS Q/Q66.40% Profit Margin- Rel Volume0.29 Prev Close10.00
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume3.63M Price10.36
Recom1.80 SMA200.40% SMA5019.81% SMA20093.98% Volume816,695 Change3.65%
Jun-28-18Initiated Raymond James Outperform
Jun-01-18Reiterated Laidlaw Buy $10 → $15
May-31-18Reiterated Maxim Group Buy $8 → $14
Mar-26-18Resumed H.C. Wainwright Buy $11
Nov-28-17Reiterated Maxim Group Buy $5 → $8
Nov-21-17Initiated ROTH Capital Buy
Nov-10-17Resumed H.C. Wainwright Buy $7
Jul-17-17Reiterated H.C. Wainwright Buy $5 → $7
Aug-11-16Reiterated Laidlaw Buy $20 → $10
May-24-16Initiated Maxim Group Buy $5
Apr-07-16Initiated H.C. Wainwright Buy $6
Jul-17-18 07:05AM  Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting PR Newswire -8.38%
Jul-14-18 07:16AM  3 Biotech Stocks With Big News Coming in NASH Motley Fool
Jul-13-18 07:31AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-08-18 09:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jun-26-18 11:27AM  Viking Therapeutics, Buy the Dip? Motley Fool
07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-20-18 06:01AM  3 Small-Cap Biotech Stocks to Keep on Your Radar Motley Fool
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool +10.49%
09:40AM  3 Growth Stocks at Deep-Value Prices Motley Fool
08:10AM  Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-14-18 10:30AM  Are These Red-Hot NASH Stocks Still a Buy? Motley Fool
Jun-13-18 04:03PM  Here's Why Viking Therapeutics Rose as Much as 14.9% Today Motley Fool +9.09%
Jun-12-18 02:15PM  VKTX: Final Patient Enrolled in P2 Trial of VK2809; Raises Gross Proceeds of $77.6M in Public Offering Zacks Small Cap Research
07:05AM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
Jun-11-18 10:31AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool +8.59%
Jun-08-18 09:18AM  Now's the Time to Buy These 3 Stocks Motley Fool
Jun-07-18 08:30AM  Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock PR Newswire +6.39%
Jun-06-18 04:01PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
08:15AM  Viking Therapeutics Recent VK2809 Update, Analyst Review and Target ACCESSWIRE
Jun-05-18 07:40AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
07:01AM  Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease PR Newswire
Jun-02-18 04:10PM  Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal Benzinga
07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-01-18 10:00AM  VKTX: Positive Data from Madrigal is Positive for Viking; Raising Valuation to $16 Zacks Small Cap Research
09:07AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and Viking Therapeutics ACCESSWIRE
05:10AM  Viking Therapeutics Breaks Out to Key Resistance Levels Investopedia
May-31-18 04:02PM  Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug Forbes +101.01%
12:27PM  Why Viking Therapeutics Stock Is On Fire Today Motley Fool
May-29-18 10:24AM  5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace
May-14-18 11:30AM  VKTX: Enrollment of Phase 2 Trial of VK2809 Nearing Completion Zacks Small Cap Research
May-09-18 04:05PM  Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
May-04-18 08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-02-18 07:30AM  Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018 PR Newswire +5.20%
Apr-30-18 04:07PM  William Blair Initiates Viking With An Outperform Rating After Competitor Proves Strategy Benzinga
Apr-19-18 07:55AM  Report: Developing Opportunities within Canada Goose, Viking Therapeutics, Vector Group, Bruker, Air Transport Services Group, and Raymond James Financial Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-13-18 11:19AM  What Should Investors Know About Viking Therapeutics Incs (NASDAQ:VKTX) Future? Simply Wall St.
Apr-12-18 08:00AM  Why Viking Therapeutics, Inc. Stock Cratered in March Motley Fool +5.20%
Mar-09-18 10:15AM  VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020 Zacks Small Cap Research
Mar-08-18 12:45PM  Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today Motley Fool -6.17%
Mar-07-18 04:05PM  Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update PR Newswire
12:15PM  Viking Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-18 07:00AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire -5.61%
Feb-28-18 11:33AM  Penny Stocks to Watch for March 2018 Investopedia
07:00AM  Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018 PR Newswire
Feb-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Programs and Systems New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-08-18 04:22PM  Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)? Simply Wall St. -8.51%
07:30AM  Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs? ACCESSWIRE
Feb-07-18 07:05AM  Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference PR Newswire +16.08%
Feb-06-18 04:05PM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire -5.39%
Feb-02-18 03:50PM  Viking Therapeutics Inc Now Has Cash Runway to Hit Multiple Catalysts Through 2020; Jason McCarthy Chimes in SmarterAnalyst +14.31%
08:33AM  Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock PR Newswire
Feb-01-18 04:01PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
02:49PM  Should You Be Concerned About Viking Therapeutics Incs (NASDAQ:VKTX) Risks? Simply Wall St.
Jan-30-18 03:27PM  Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk TheStreet.com -8.93%
Jan-24-18 12:00PM  VKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 Trial Zacks Small Cap Research
Jan-02-18 07:05AM  Viking Therapeutics to Present at Biotech Showcase 2018 PR Newswire +10.34%
Dec-29-17 05:05PM  What Should We Expect From Viking Therapeutics Incs (NASDAQ:VKTX) Earnings Over The Next Few Years? Simply Wall St.
Dec-11-17 04:15PM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace +10.27%
Dec-06-17 08:08PM  Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock PR Newswire +9.12%
Dec-05-17 04:18PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Nov-30-17 07:40AM  Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture ACCESSWIRE +12.59%
Nov-28-17 04:00PM  VKTX: Positive Results From Phase 2 Study of VK5211 in Hip Fracture Zacks Small Cap Research -6.62%
07:44AM  Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment MarketWatch
07:02AM  Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture PR Newswire
Nov-20-17 08:20AM  Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Nov-09-17 02:30PM  VKTX: Data From Phase 2 Trial of VK5211 to be Reported Soon Zacks Small Cap Research
Nov-08-17 04:05PM  Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire -6.93%
Nov-01-17 07:30AM  Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 PR Newswire
Oct-31-17 08:00AM  Viking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts Target ACCESSWIRE
Oct-26-17 01:00PM  VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds Zacks Small Cap Research -6.52%
07:20AM  Featured Company News - Viking Presents Positive Results From In Vivo Study of VK2809 in NASH at the Annual Meeting of AASLD ACCESSWIRE
Oct-24-17 07:05AM  Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) PR Newswire -5.36%
Oct-23-17 07:05AM  Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association PR Newswire -6.67%
Oct-11-17 11:30AM  VKTX: KOLs Highlight Necessity For Effective Hip Fracture Treatment Zacks Small Cap Research
Oct-04-17 07:05AM  Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) PR Newswire +8.62%
Oct-02-17 07:20AM  Corporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park Capital ACCESSWIRE
Sep-29-17 07:05AM  Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital PR Newswire +6.11%
Sep-25-17 07:30AM  Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings PR Newswire +5.04%
Sep-21-17 06:21PM  Should You Buy Viking Therapeutics Inc (VKTX) Now? Simply Wall St.
Sep-12-17 11:00AM  VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH Zacks Small Cap Research +8.62%
Sep-11-17 07:05AM  Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
Sep-07-17 07:02AM  Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) PR Newswire +6.67%
Sep-05-17 07:30AM  Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference PR Newswire
Aug-14-17 04:00PM  VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17 Zacks Small Cap Research
Aug-09-17 04:05PM  Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Aug-02-17 07:30AM  Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 PR Newswire -9.71%
Jul-14-17 07:20AM  Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture Accesswire
Jul-12-17 07:00AM  Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture PR Newswire
Jul-06-17 08:00AM  Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors PR Newswire
Jun-19-17 11:00AM  VKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering Zacks Small Cap Research
Jun-14-17 09:55AM  Viking Therapeutics Announces $4.3 Million Registered Direct Offering PR Newswire -11.11%
Jun-08-17 08:15AM  Featured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis Accesswire
Jun-07-17 01:00PM  VKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model Zacks Small Cap Research
Jun-06-17 07:14AM  Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
May-31-17 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
May-12-17 04:00PM  VKTX: Multiple Data Readouts Ahead in 2017 Zacks Small Cap Research -6.87%
May-10-17 04:05PM  Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-03-17 07:30AM  Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017 PR Newswire
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SINGLETON J MATTHEWDirectorMay 31Buy9.829,50093,2619,500May 31 07:04 PM
MORNEAU MICHAELVP, Finance and AdministrationMay 31Sale9.2521,551199,34794,035May 31 07:03 PM
MACARTNEY LAWSONDirectorMay 29Buy5.2247,965250,32947,965May 31 06:57 PM
Rowland Charles A JrDirectorMay 29Buy5.1630,000154,80030,000May 31 07:02 PM
Webster Stephen WDirectorMay 29Buy5.218,00041,7128,000May 31 06:59 PM